---
title: "According to \"The Big Bank,\" Bank of America Securities raised the target price for WuXi Biologics to 41.8 yuan, expecting rapid business growth"
description: "Bank of America Securities raised the target price for WuXi Biologics to RMB 41.8, expecting the company's business to grow rapidly. The report pointed out that WuXi Biologics added 209 comprehensive "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/272487224.md"
published_at: "2026-01-14T02:27:28.000Z"
---

# According to "The Big Bank," Bank of America Securities raised the target price for WuXi Biologics to 41.8 yuan, expecting rapid business growth

> Bank of America Securities raised the target price for WuXi Biologics to RMB 41.8, expecting the company's business to grow rapidly. The report pointed out that WuXi Biologics added 209 comprehensive projects last year, a growth of 38%, of which two-thirds were composite models, and about half came from U.S. clients. The company holds 945 projects, and revenue forecasts for 2025, 2026, and 2027 have been raised by 1%, 5%, and 8%, respectively. The bank maintains a "Neutral" rating on WuXi Biologics, as business development meets expectations but faces potential geopolitical risks

According to a research report by Bank of America Securities, WuXi Biologics (02269.HK) added 209 integrated projects last year, a year-on-year increase of 38%, of which two-thirds are composite models (bispecific and multispecific antibodies and antibody-drug conjugates), with about half coming from U.S. clients. In addition, the company also obtained 23 projects last year, including 6 late-stage projects, of which about half are from U.S. clients, and over 50% are composite models.

As of the fiscal year 2025, the company holds 945 projects, including 463 in the preclinical stage, 289 in Phase I clinical, 94 in Phase II clinical, 74 in Phase III clinical, and 25 in the commercialization stage.

To reflect the rapid development of the company in research and development and production stages last year, and considering the high growth visibility of its CMO business, the bank has raised its revenue forecasts for 2025 to 2027 by 1%, 5%, and 8% respectively, and increased the target price from HKD 35 to HKD 41.8. The bank reiterates WuXi Biologics' "Neutral" rating, as the company's business development meets expectations and its leading position is consolidated, but is simultaneously offset by potential geopolitical risks from the Biosecurity Act

### Related Stocks

- [WXXWY.US - WuXi Biologics](https://longbridge.com/en/quote/WXXWY.US.md)
- [02269.HK - WUXI BIO](https://longbridge.com/en/quote/02269.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| WuXi XDC Launches Cash Offer to Acquire All Remaining Shares of BioDlink | WuXi XDC Cayman Inc. has launched a voluntary conditional cash offer to acquire all remaining shares of BioDlink not alr | [Link](https://longbridge.com/en/news/275670240.md) |
| Zhongtai Securities Reaffirms Their Buy Rating on Wuxi Biologics (Cayman) (WXIBF) | In a report released yesterday, from Zhongtai Securities maintained a Buy rating on Wuxi Biologics (Cayman), with a pric | [Link](https://longbridge.com/en/news/275971177.md) |
| State of Wyoming Cuts Stake in Clear Channel Outdoor Holdings, Inc. $CCO | The State of Wyoming significantly reduced its stake in Clear Channel Outdoor Holdings, Inc. by 96.5% in Q3, now holding | [Link](https://longbridge.com/en/news/275882777.md) |
| Polaris Insider Sold Shares Worth $520,335, According to a Recent SEC Filing | 04:29 AM EST, 02/13/2026 (MT Newswires) -- Robert Paul Mack, Chief Financial Officer, Executive Vice President of Financ | [Link](https://longbridge.com/en/news/275881976.md) |
| Leuthold Group LLC Acquires Shares of 7,546 United Therapeutics Corporation $UTHR | Leuthold Group LLC acquired 7,546 shares of United Therapeutics Corporation (NASDAQ: UTHR) during Q3, valued at approxim | [Link](https://longbridge.com/en/news/275762494.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.